Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by D. Campion.
Nature Genetics | 2009
Jean-Charles Lambert; S Heath; G Even; D. Campion; K Sleegers; M Hiltunen; O Cambarros; Diana Zelenika; María J. Bullido; B Tavernier; L Letenneur; Karolien Bettens; Claudine Berr; Florence Pasquier; N Fiévet; P Barbager-Gateau; S. Engelborghs; P De Deyn; I Mateo; A Franck; S Helisalmi; E Porcellini; O Hanon; M de Pancorbo; C Lendon; C Dufouil; C Jaillard; T Leveillard; Alvarez; P Bosco
The gene encoding apolipoprotein E (APOE) on chromosome 19 is the only confirmed susceptibility locus for late-onset Alzheimers disease. To identify other risk loci, we conducted a large genome-wide association study of 2,032 individuals from France with Alzheimers disease (cases) and 5,328 controls. Markers outside APOE with suggestive evidence of association (P < 10−5) were examined in collections from Belgium, Finland, Italy and Spain totaling 3,978 Alzheimers disease cases and 3,297 controls. Two loci gave replicated evidence of association: one within CLU (also called APOJ), encoding clusterin or apolipoprotein J, on chromosome 8 (rs11136000, OR = 0.86, 95% CI 0.81–0.90, P = 7.5 × 10−9 for combined data) and the other within CR1, encoding the complement component (3b/4b) receptor 1, on chromosome 1 (rs6656401, OR = 1.21, 95% CI 1.14–1.29, P = 3.7 × 10−9 for combined data). Previous biological studies support roles of CLU and CR1 in the clearance of β amyloid (Aβ) peptide, the principal constituent of amyloid plaques, which are one of the major brain lesions of individuals with Alzheimers disease.
Molecular Psychiatry | 2013
Julien Chapuis; Franck Hansmannel; Marc Gistelinck; Anais Mounier; C Van Cauwenberghe; Kristof Van Kolen; F Geller; Y Sottejeau; D Harold; Pierre Dourlen; Benjamin Grenier-Boley; Yoichiro Kamatani; B Delepine; F Demiautte; Diana Zelenika; Nadège Zommer; Malika Hamdane; Céline Bellenguez; J.-F. Dartigues; J-J Hauw; F Letronne; A-M Ayral; K Sleegers; A Schellens; Lies Vanden Broeck; S. Engelborghs; P.P. De Deyn; Rik Vandenberghe; Michael Conlon O'Donovan; Michael John Owen
Genome-wide association studies (GWAS) have identified a region upstream the BIN1 gene as the most important genetic susceptibility locus in Alzheimer’s disease (AD) after APOE. We report that BIN1 transcript levels were increased in AD brains and identified a novel 3 bp insertion allele ∼28 kb upstream of BIN1, which increased (i) transcriptional activity in vitro, (ii) BIN1 expression levels in human brain and (iii) AD risk in three independent case-control cohorts (Meta-analysed Odds ratio of 1.20 (1.14–1.26) (P=3.8 × 10−11)). Interestingly, decreased expression of the Drosophila BIN1 ortholog Amph suppressed Tau-mediated neurotoxicity in three different assays. Accordingly, Tau and BIN1 colocalized and interacted in human neuroblastoma cells and in mouse brain. Finally, the 3 bp insertion was associated with Tau but not Amyloid loads in AD brains. We propose that BIN1 mediates AD risk by modulating Tau pathology.
Neurology | 2006
Lucie Guyant-Maréchal; Annie Laquerrière; Charles Duyckaerts; C. Dumanchin; Jacqueline Bou; F. Dugny; I. Le Ber; Thierry Frebourg; Didier Hannequin; D. Campion
Background: Hereditary inclusion body myopathy (IBMPFD) with Paget disease of bone (PDB) and frontotemporal dementia (FTD) is a rare multisystem disorder with autosomal dominant inheritance. Recently, missense mutations in the gene encoding valosin-containing protein (VCP) have been found in individuals with IBMPFD. VCP/P97, which exerts a variety of cellular functions, plays a key role in the ubiquitin-proteasome dependent degradation of cytosolic proteins and in the retrotranslocation of misfolded proteins from the endoplasmic reticulum into the cytoplasm. Methods: The authors describe the clinical features of two kindreds in which VCP R93C and R155C missense mutations segregate and perform a histopathologic examination of brain, muscle, bone, and liver of three subjects harboring the R155C mutation. Results: Frontotemporal dementia was present in 100% of affected subjects in Family F1 and 70% in Family F2, as compared with an average of 30% in previously described IBMPFD families. In contrast, PDB was a more inconstant clinical feature. Biochemical and histopathologic data are consistent with the hypothesis that VCP R155C mutation disrupts normal VCP function, leading to diffuse accumulation of ubiquitinated proteins within the cells. Conclusions: VCP mutations are present in two families in which FTD is the most prominent symptom. The histopathologic study performed in patients harboring the R155C mutation supports the hypothesis that this mutation disrupts normal VCP function, leading to diffuse accumulation of ubiquitinated proteins within the cells. IBMPFD belongs to a class of genetic diseases associated with an alteration of the ubiquitin-proteasome system.
Neurology | 2009
I. Le Ber; Agnès Camuzat; Eric Berger; Didier Hannequin; Annie Laquerrière; Véronique Golfier; Danielle Seilhean; Gabriel Viennet; Philippe Couratier; Patrice Verpillat; S. Heath; William Camu; Olivier Martinaud; L. Lacomblez; Martine Vercelletto; François Salachas; François Sellal; Mira Didic; Catherine Thomas-Antérion; Michèle Puel; B.-F. Michel; C. Besse; Charles Duyckaerts; Vincent Meininger; D. Campion; Bruno Dubois; Alexis Brice
Background: Frontotemporal dementia associated with motor neuron disease (FTD-MND) is a rare neurodegenerative disorder that may be inherited by autosomal dominant trait. No major gene has been identified but a locus was mapped on chromosome 9 (9p21.3-p13.3). Methods: Ten French families with FTD-MND were tested for linkage to the 9p21.3-p13.3 region. We report extensive mutation screening in 9p-linked families and their clinical characteristics. Results: We identified six new families with evidence for linkage to the chromosome 9p. Cumulative multipoint LOD score values were positive between markers D9S1121 and D9S301, reaching a peak of 8.0 at marker D9S248. Haplotype reconstruction defined the telomeric boundary at marker AFM218xg11, slightly narrowing the candidate interval. We found no disease-causing mutations by sequencing 29 candidate genes including IFT74 and no copy number variations in the 9p region. The mean age at onset was 57.9 ± 10.3 years (range, 41–84), with wide heterogeneity within and among families suggesting age-dependant penetrance. The patients presented isolated FTD (32%), isolated MND (29%), or both disorders (39%). The general characteristics of the disease did not differ, except for an older age at onset and shorter disease duration in the 9p-linked compared to nonlinked families. TDP-43-positive neuronal cytoplasmic inclusions were found in cortex and spinal cord in 3 patients. Conclusions: This study increases the number of 9p-linked families now reported and shows that this locus may have a major effect on frontotemporal dementia (FTD) and motor neuron disease (MND). Considering our results, the causative gene might be implicated in at least 60% of the families with FTD-MND disorder.
Neurology | 2007
Lucie Guyant-Maréchal; Anne Rovelet-Lecrux; L. Goumidi; E. Cousin; Didier Hannequin; G. Raux; C. Penet; S. Ricard; S. Macé; Philippe Amouyel; Jean-Francois Deleuze; Thierry Frebourg; Alexis Brice; Jean-Charles Lambert; D. Campion
We genotyped five polymorphisms, including two polymorphisms with known effects on transcriptional activity, in a large cohort of 427 Alzheimer disease (AD) cases and 472 control subjects. An association between rs463946 (−3102 G/C) and AD was found and was confirmed in a replication sample of a similar size. By contrast, analysis of three recently described rare mutations influencing APP transcription did not confirm their association with AD risk.
Neurology | 2008
I. Guyant-Marechal; Eric Berger; Annie Laquerrière; Anne Rovelet-Lecrux; Gabriel Viennet; Thierry Frebourg; Lucien Rumbach; D. Campion; Didier Hannequin
Different APP locus duplications have been recently identified in rare families with autosomal dominant early onset Alzheimer disease (AD) and Aβ-related cerebral amyloid angiopathy (CAA).1–3 We report a novel family revealing a very large diversity of phenotype including dementia with Lewy bodies (DLB). ### Methods. Family members gave informed consent according to a protocol approved by the ethics committees of the CCPPRB Pitie-Salpetriere and Paris-Necker. Characterization of five patients, with two detailed neuropsychological evaluations, brain MRI of three patients, and one neuropathologic evaluation, were assessed. APP locus was analyzed by quantitative multiplex PCR of short fluorescent fragments (QMPSF) in three patients. Patients were considered affected if they had dementia, intracerebral hemorrhage (ICH), or epilepsy (e-Methods on the Neurology ® Web site at www.neurology.org). ### Results. The proband (II-1, figure e-1) developed bradykinesia, memory problems, and apraxia when she was 44 years old. She developed paranoid delusion with visual hallucinations at 50 years of age. The association with bilateral tremor, rigidity, and bradykinesia was suggestive of DLB. Several T2 lesions were noted on MRI. She died at 55 years of age. Patients I-2 and I-3 had progressive memory disturbances with behavioral changes suggestive of AD since they were 55 and 60 years of age. Patient II-3 had partial visual seizures at the age …
Molecular Psychiatry | 2016
Gaël Nicolas; Camille Charbonnier; David Wallon; Olivier Quenez; Céline Bellenguez; Benjamin Grenier-Boley; Stéphane Rousseau; A-C Richard; Anne Rovelet-Lecrux; K Le Guennec; Delphine Bacq; J-G Garnier; Robert Olaso; Anne Boland; Vincent Meyer; J-F Deleuze; Philippe Amouyel; Hans Markus Munter; Guillaume Bourque; Mark Lathrop; Thierry Frebourg; Richard Redon; Luc Letenneur; J.-F. Dartigues; Emmanuelle Génin; J-C Lambert; Didier Hannequin; D. Campion
The SORL1 protein plays a protective role against the secretion of the amyloid β peptide, a key event in the pathogeny of Alzheimer’s disease. We assessed the impact of SORL1 rare variants in early-onset Alzheimer’s disease (EOAD) in a case–control setting. We conducted a whole exome analysis among 484 French EOAD patients and 498 ethnically matched controls. After collapsing rare variants (minor allele frequency ≤1%), we detected an enrichment of disruptive and predicted damaging missense SORL1 variants in cases (odds radio (OR)=5.03, 95% confidence interval (CI)=(2.02–14.99), P=7.49.10−5). This enrichment was even stronger when restricting the analysis to the 205 cases with a positive family history (OR=8.86, 95% CI=(3.35–27.31), P=3.82.10−7). We conclude that predicted damaging rare SORL1 variants are a strong risk factor for EOAD and that the association signal is mainly driven by cases with positive family history.
Molecular Psychiatry | 2017
K Le Guennec; Olivier Quenez; Gaël Nicolas; David Wallon; Stéphane Rousseau; A-C Richard; John Franklin Alexander; Peristera Paschou; Camille Charbonnier; Céline Bellenguez; Benjamin Grenier-Boley; Doris Lechner; M-T Bihoreau; Robert Olaso; Anne Boland; Vincent Meyer; J-F Deleuze; Philippe Amouyel; Hans Markus Munter; Guillaume Bourque; Mark Lathrop; Thierry Frebourg; Richard Redon; Luc Letenneur; J.-F. Dartigues; Olivier Martinaud; Ognian Kalev; Shima Mehrabian; Latchezar Traykov; Thomas Ströbel
To assess the role of rare copy number variations in Alzheimers disease (AD), we conducted a case–control study using whole-exome sequencing data from 522 early-onset cases and 584 controls. The most recurrent rearrangement was a 17q21.31 microduplication, overlapping the CRHR1, MAPT, STH and KANSL1 genes that was found in four cases, including one de novo rearrangement, and was absent in controls. The increased MAPT gene dosage led to a 1.6–1.9-fold expression of the MAPT messenger RNA. Clinical signs, neuroimaging and cerebrospinal fluid biomarker profiles were consistent with an AD diagnosis in MAPT duplication carriers. However, amyloid positon emission tomography (PET) imaging, performed in three patients, was negative. Analysis of an additional case with neuropathological examination confirmed that the MAPT duplication causes a complex tauopathy, including prominent neurofibrillary tangle pathology in the medial temporal lobe without amyloid-β deposits. 17q21.31 duplication is the genetic basis of a novel entity marked by prominent tauopathy, leading to early-onset dementia with an AD clinical phenotype. This entity could account for a proportion of probable AD cases with negative amyloid PET imaging recently identified in large clinical series.
Molecular Psychiatry | 2016
D. Campion; C Pottier; Gaël Nicolas; K Le Guennec; Anne Rovelet-Lecrux
In genetically complex diseases, the search for missing heritability is focusing on rare variants with large effect. Thanks to next generation sequencing technologies, genome-wide characterization of these variants is now feasible in every individual. However, a lesson from current studies is that collapsing rare variants at the gene level is often insufficient to obtain a statistically significant signal in case–control studies, and that network-based analyses are an attractive complement to classical approaches. In Alzheimer disease (AD), according to the prevalent amyloid cascade hypothesis, the pathology is driven by the amyloid beta (Aβ) peptide. In past years, based on experimental studies, several hundreds of proteins have been shown to interfere with Aβ production, clearance, aggregation or toxicity. Thanks to a manual curation of the literature, we identified 335 genes/proteins involved in this biological network and classified them according to their cellular function. The complete list of genes, or its subcomponents, will be of interest in ongoing AD genetic studies.
Archive | 2009
D. Campion; David M. Kane; Nicholas Dwork; Matthew Michael Pohlman; Randall Edward Potter